This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ9M052_L.jpg
Indivior had in June agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states regarding the claims.
The agreement with the direct purchasers will mark the end of the multi-district litigation relating to Suboxone, it said.
Indivior said it will take a charge of $228 million in the third quarter, above the current remaining provision of $157 million, which will be excluded from adjusted earnings.
